uniQure Secures Up to $175 Million in Non-Dilutive Loan Facility with Hercules Capital to Support Potential AMT-130 Launch
**uniQure Secures Up to $175 Million in New Non-Dilutive Loan Facility** LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 - uniQure N.V. (Nasdaq: QURE), a leader in gene therapy, has announced the refinancing of its existing $50 million debt and has secured a new senior secured term loan facility of up to $175 million with Hercules Capital, Inc. $(HTGC)$. The agreement extends the term of the current $50 million debt from January 2027 to October 2030 and provides access to an additional $125 million, subject to regulatory, financial, and lender approval milestones. The facility consists of three tranches: a $50 million refinancing, an additional $100 million accessible upon meeting certain regulatory and financial milestones related to AMT-130 (its investigational Huntington's disease therapy), and a further $25 million available with Hercules' approval. The loan carries a floating interest rate starting at 9.70%, lower than the previous rate of 11.95%. uniQure's CFO Christian Klemt said the transaction enhances the company's financial flexibility as it prepares for a potential commercial launch of AMT-130 in the U.S., anticipated in 2026. Leerink Partners advised uniQure on the financing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534223-en) on September 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.